interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Pegcetacoplan

Generic competition · all medicines · read 12 November 2026

Is there a generic of Pegcetacoplan, and who makes it?

Pegcetacoplan appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Pegcetacoplan2 dosage-form groups in the Orange Book
0generic makers listed
  1. Pegcetacoplan appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Intravitreal

Brand listed, no generic listed as marketed

Brand listed as marketed: Syfovre. No generic is listed as marketed.

2020202520302035204001brand 2023data datePatent 8168584 listed to expire 7 April 2027Patent 9169307 listed to expire 18 November 2027Patent 7989589 listed to expire 4 December 2027Patent 7888323 listed to expire 4 December 2027Patent 11661441 listed to expire 13 January 2033Patent 10125171 listed to expire 2 August 2033Patent 11292815 listed to expire 15 November 2033Patent 10875893 listed to expire 15 November 2033Patent 10035822 listed to expire 15 November 2033Patent 12528836 listed to expire 7 October 2036Patent 11903994 listed to expire 22 February 2037Patent 12458695 listed to expire 14 December 2038
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 7 April 2027Patent 8168584
  • 18 November 2027Patent 9169307 drug substance
  • 4 December 2027Patent 7989589 drug substance
  • 4 December 2027Patent 7888323 drug substance
  • 13 January 2033Patent 11661441 drug substance
  • 2 August 2033Patent 10125171 drug substance
  • 15 November 2033Patent 11292815 drug substance
  • 15 November 2033Patent 10875893 drug substance

4 more patents are listed.

Solution, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Empaveli. No generic is listed as marketed.

2020202520302035204001brand 2021data datePatent 9169307 listed to expire 18 November 2027Patent 7989589 listed to expire 4 December 2027Patent 7888323 listed to expire 4 December 2027Patent 11661441 listed to expire 13 January 2033Patent 10125171 listed to expire 2 August 2033Patent 11292815 listed to expire 15 November 2033Patent 10875893 listed to expire 15 November 2033Patent 10035822 listed to expire 15 November 2033Patent 11040107 listed to expire 9 April 2038Patent 11844841 listed to expire 9 December 2038Patent 12290566 listed to expire 14 December 2038Exclusivity ODE-351 to 14 May 2028Exclusivity I-972 to 28 July 2028Exclusivity ODE-533 to 28 July 2032Exclusivity ODE-539 to 28 July 2032
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 14 May 2028Exclusivity ODE-351 Empaveli
  • 28 July 2028Exclusivity I-972 Empaveli
  • 28 July 2032Exclusivity ODE-533 Empaveli
  • 28 July 2032Exclusivity ODE-539 Empaveli
  • 18 November 2027Patent 9169307 drug substance
  • 4 December 2027Patent 7989589 drug substance
  • 4 December 2027Patent 7888323 drug substance
  • 13 January 2033Patent 11661441 drug substance
  • 2 August 2033Patent 10125171 drug substance
  • 15 November 2033Patent 11292815 drug substance
  • 15 November 2033Patent 10875893 drug substance
  • 15 November 2033Patent 10035822 drug substance

3 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.